Anti-CD40L immunotoxins for the treatment of diseases
AssigneeTanox Pharma B.V.
InventorsMark Boer De, Marcel Theodorus Hartog Den
Life of this patent
Estimating the term…
Abstract
An immunotoxin molecule is described which comprises an antibody specific for human CD40L antigen located on the surface of a human cell, coupled to a toxin molecule or active fragment thereof, wherein the binding of the immunotoxin to the CD40L molecule results in the killing of the CD40L expressing cell. The toxin molecule is especially a type-1 ribosome inactivating protein, or an active fragment thereof. The immunotoxin can be used for the treatment of autoimmune diseases such as multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus, or T-cell malignancies.
Claims11
An immunotoxin molecule comprising an antibody, or a binding fragment thereof, specific for human CD40L antigen conjugated to a Type I ribosome inactivating protein comprising SEQ ID NO 1, wherein the binding of said immunotoxin molecule to the CD40L molecule results in the killing of the CD40L expressing cell.
An immunotoxin molecule comprising an antibody, or a binding fragment thereof, specific for human CD40L antigen conjugated to a Type I ribosome inactivating protein isolated from Bougainvillea spectabilis Willd characterized as having a molecular weight of about 26,000 daltons by polyacrylamide gel electrophoresis under reducing and non-reducing conditions, wherein the binding of said immunotoxin molecule to the CD40L molecule results in the killing of the CD40L expressing cell.
Dependencies are inferred from the claim text.